Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | CTSS | P25774 | 3/20 | 0.49 |
| ▸ | CTSK | P43235 | 2/20 | 0.49 |
| ▸ | SYK | P43405 | 1/20 | 0.49 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.47 |
| ▸ | GABBR1 | Q9UBS5 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 2/20 | 0.46 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.44 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.44 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.42 |
| ▸ | IDO1 | P14902 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | FNTA | P49354 | 2/20 | 0.41 |
| ▸ | FNTB | P49356 | 2/20 | 0.41 |
| ▸ | CTSL | P07711 | 1/20 | 0.41 |
| ▸ | CTSB | P07858 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16680112 | 1.00 | MAPT (0.54) | MAPTGAACTSSCTSKSYK | |
| SCHEMBL5085011 | 0.89 | SYK (0.47) | MAPTGAACTSSCTSKSYK | |
| SCHEMBL20773522 | 0.89 | SYK (0.47) | MAPTGAACTSSCTSKSYK | |
| SCHEMBL21610479 | 0.89 | CTSS (0.47) | MAPTGAACTSSCTSKSYK | |
| SCHEMBL1998566 | 0.88 | ATM (0.59) | MAPTGAASYKGABBR2GABBR1 | |
| SCHEMBL637735 | 0.88 | ATM (0.59) | MAPTGAASYKGABBR2GABBR1 | |
| SCHEMBL16798314 | 0.87 | SYK (0.48) | MAPTGAACTSSCTSKSYK | |
| SCHEMBL21609312 | 0.87 | PTGFR (0.47) | MAPTGAACTSSCTSKSYK | |
| SCHEMBL29848250 | 0.87 | PTGFR (0.47) | MAPTGAACTSSCTSKSYK | |
| SCHEMBL5742834 | 0.87 | CTSK (0.50) | MAPTGAACTSSCTSKSYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210380548-A1 | Fused [1,2,4]Thiadiazine Derivatives Which Act as KAT Inhibitors of the MYST Family | CTXT PTY LIMITED (AU) | 2021-12-09 | — | — | US | disclosed |
| WO-2019043139-A1 | FUSED [1,2,4]THIADIAZINE DERIVATIVES WHICH ACT AS KAT INHIBITORS OF THE MYST FAMILY | CTXT PTY LIMITED (AU) | 2019-03-07 | — | — | WO | disclosed |
| US-9452990-B2 | Complement pathway modulators and uses thereof | NOVARTIS AG (CH) | 2016-09-27 | — | — | US | disclosed |
| EP-2864322-B1 | COMPLEMENT PATHWAY MODULATORS AND USES THEREOF | NOVARTIS AG (CH) | 2016-04-27 | — | — | EP | disclosed |
| US-20150126492-A1 | Complement Pathway Modulators and Uses Thereof | NOVARTIS AG (CH) | 2015-05-07 | — | — | US | disclosed |
| EP-1968568-A2 | INHIBITORS OF Akt ACTIVITY | SmithKline Beecham Corporation (US) | 2008-09-17 | — | — | EP | disclosed |
| WO-2007076423-A2 | INHIBITORS OF Akt ACTIVITY | SMITHKLINE BEECHAM CORPORATION (US) | 2007-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210380548-A1 | Fused [1,2,4]Thiadiazine Derivatives Which Act as KAT Inhibitors of the MYST Family | KAT5, KAT6A, KAT2A | MAPT 422/4885GAA 4343/4885CTSS 4370/4885 |
| US-20150126492-A1 | Complement Pathway Modulators and Uses Thereof | CFB, CFH, TFPI | MAPT 3161/4885GAA 2871/4885CTSS 2195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.